On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
Browsing: Small Cell Lung Cancer
Introduction:In a comprehensive presentation, Dr. Jacob Sands, MD, a medical oncologist, delves into the treatment options for small cell lung…
…IntroductionSmall cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited benefit due…
By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
A new CAR T-cell therapy strategy has shown significant effectiveness against small cell lung cancer, according to a preclinical study…
iFrame is not supported! CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD By Reiner Brentjens,…
For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and…
iFrame is not supported! What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting question,…
REPLATINUM Phase III Update [2022] What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting…
John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer…
John H. Bushweller, Ph.D., Professor, Molecular Physiology and Biological Physics at the University of Virginia, Program Leader at UVA Cancer…
Melissa L. Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute speaks about Rovalpituzumab Tesirine as a Maintenance…
Melissa L. Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute speaks about Rovalpituzumab Tesirine as a Maintenance…
Professor William North, Professor Emeritus of Physiology and Neurobiology at the Geisel School of Medicine at Dartmouth College and was…
Joel Neal, MD, Ph.D., Associate Professor Of Medicine (Oncology) from Stanford Cancer Institute/Stanford University speaks about Randomized Phase II Study…
Jared Weiss, MD, Associate Professor Clinical Research Hematology/Oncology from Cancer Grace speaks about FDA Approves First Therapy Developed to Help…
Jacob Scott, MD, DPhil of the Cleveland Clinic speaks about Combining Genomics and Mathematics Helps Personalize Radiation Therapy for Lung…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.…
We are happy to present more videos for the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.…
For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Jeff Petty, MD Wake Forest Baptist Health discusses Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelcaâ„¢ (lurbinectedin) for the…
Raj Malik, MD – G1 Therapeutics discusses G1 Therapeutics to present data showing myelopreservation benefits of Trilaciclib in patients with…
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium…
Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium…
The standard of care for small-cell lung cancer (SCLC) had been unchanged for over 20 years, with platinum-based chemotherapy being…
United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan…
– Jazz to pay an upfront payment of $200 million to PharmaMar – Opportunity for Jazz to expand its oncology…
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in…
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy…
Jacob Sands, MD explica lurbinectedin presentado en ASCO 2019.
Jacob Sands, MD discusses lurbinectedin providing another treatment option for patients and practitioners.
Jacob Sands, MD discusses lurbinectedin presented at ASCO 2019.
Jacob Sands, MD provides data and updates on lurbinectedin in small cell lung cancer immunotherapy treatment.
Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in…
Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar…
PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute shares the mechanism of action for trilacicnib…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the outcomes from the phase II…
Rafael Santana-Davila MD @valdesan Of Fred Hutchinson Cancer Research Center Discusses Lurbinecedin Data At ASCO Important & Encouraging/ Want To…
Dr. Luis Paz-Ares, MD, Phd of the Hospital Universitario 12 De Octubre gives a brief overview of his ASCO 2019…
Dr. Luiz Paz-Ares, MD, Phd of th Hospital Universitario 12 De Octubre gives a brief overview of his presentation from…
Luis G. Paz-Ares, MD, Phd provides an overview of his presentation at ASCO 2019 entitled Efficacy and safety profile of…
Luis G. Paz-Ares, MD, Phd provides an overview of his presentation at ASCO 2019 entitled Efficacy and safety profile of…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 28, 2016 Spanish Lung Cancer Library: Dr. Brian Hunis,…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2015 Dr. Vivek Mehta, radiation oncologist, reviews the…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 15, 2015 Drs. Ben Solomon, Leora Horn, & Jack…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 5, 2018 Drs. H. Jack West, Medical Director -…
Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from…
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy…
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory…
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small…
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard…
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses…
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Whats On Deck For Lurbinectedin. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference – Munich, Germany On October…
Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses Lurbinectedin Data Presented This Year. At ESMO Oncology Conference – Munich, Germany…
Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference – Munich,…
Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference – Munich,…
Pascal Besman Chief Operating Officer at PharmaMar Discusses Differences Between NSCLC & SCLC. At ESMO Oncology Conference – Munich, Germany…
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains CaM6 In Collaboration w German Cancer Ctr. | ILDR2 In Collaboration w Compugen…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Thorium Platform Based on Initial Radium (Xofigo) | Thorium Delivers Alpha Radiation at…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains DHODH Inhibitor Pyrimidine Synthesis | FGFR Inhibitor has Response Rate of 24% at…
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at Annual…
Ana Limon Carrera, Takeda Oncology, Additional Cell-Cycle Modulators is of Great Interest | Molecule w/ Safety Profile Combines Well with…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Submitting Update of Monotherapy to ESMO | Closure of ATLANTIS Trial…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Far Along Development in SCLC | American Oncologists Less Familiar w…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Development in Small Cell has been Much Slower | Most Drivers…
Pascal Besman, Chief Operating Officer of PharmaMar, talks about Lurbinectedin More Pronounced in Overall Survival | OS Endpoint is Preferable…
Pascal Besman, Chief Operating Officer of PharmaMar, shares Investigator Sponsored Trials in Europe & US | With Immuno-Oncology Checkpoint Inhibitors…
Pascal Besman, Chief Operating Officer of PharmaMar, shares a Randomized Trial of Topotecan & CAV | Monotherapy Will Have Up…
Pascal Besman, Chief Operating Officer of PharmaMar, shares an Update on Relapsed SCLC Monotherapy Trial | Overall Survival Data of…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD,…
Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the topic of lung cancer and that there is an entire spectrum…
Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to discuss…
Paul K. Paik, MD of Memorial Sloan Kettering Cancer Center discusses the PFS of FLAURA trial compared to first generation…